Viridian director granted 32,341 stock options

Viridian Therapeutics director Sarah Gheuens received a grant of stock options as part of her board compensation.

Rhea-AI Filing Summary

Viridian Therapeutics director Sarah Gheuens received a grant of stock options as part of her board compensation. She was awarded options for 32,341 shares of common stock with an exercise price of $18.48 per share, expiring on July 1, 2036. The options vest in full on the earlier of July 1, 2027 or the company’s 2027 annual meeting of stockholders, assuming she continues to serve on the board. After this grant, she holds options for 32,341 underlying shares directly.

Insider Trade Summary

Grant/Award: 32,341 shares

Grant/Award 1 txn

Insider Gheuens Sarah

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,341	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,341 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

Key Figures

Stock options granted: 32,341 shares Exercise price: $18.48 per share Underlying shares: 32,341 shares +3 more

6 metrics

Stock options granted 32,341 shares Stock Option (Right to Buy) grant to director

Exercise price $18.48 per share Conversion or exercise price for options

Underlying shares 32,341 shares Common stock underlying the option

Total options after grant 32,341 shares Total shares following transaction

Option expiration date July 1, 2036 Expiration date of the granted options

Latest vesting date July 1, 2027 Latest possible full vesting date per footnote

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 18.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-07-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Viridian Therapeutics (VRDN) report for Sarah Gheuens?

Viridian Therapeutics reported that director Sarah Gheuens received a grant of stock options for 32,341 shares. These options relate to the company’s common stock and were awarded as compensation for her service on the board of directors.

How many Viridian Therapeutics (VRDN) shares are covered by Sarah Gheuens’ new stock options?

The new stock option grant to Sarah Gheuens covers 32,341 shares of Viridian Therapeutics common stock. This entire amount reflects her post-transaction option holdings as disclosed in the filing’s total shares following the transaction.

What is the exercise price and expiration date of Sarah Gheuens’ Viridian (VRDN) stock options?

The stock options granted to Sarah Gheuens have an exercise price of $18.48 per share and expire on July 1, 2036. She can choose to exercise these options at that price any time before they expire, subject to vesting.

When do Sarah Gheuens’ Viridian Therapeutics (VRDN) stock options vest?

The options vest in full on the earlier of July 1, 2027 or Viridian Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on her continued service on the company’s board of directors through that vesting date.

Is Sarah Gheuens’ Viridian (VRDN) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 transaction for Sarah Gheuens is a compensation-related stock option grant, coded as an acquisition (A). She did not buy shares in the market; she received options as an award tied to her board role.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gheuens Sarah

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	07/01/2026		A		32,341		(1)	07/01/2036	Common Stock	32,341	$0.00	32,341	D

Explanation of Responses:

1. The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

	/s/ Jennifer Tousignant, Attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)